Yoshihiko Tomita

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 11

Top Topics

Clinical Practice

Cross Sectional

Renal Cell Carcinoma

Top Venues

International journal of urology : official journal of the Japanese Urological Association

Japanese journal of clinical oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Taigo Kato, Yuzo Nakano, Fumiya Hongo, Hidenori Katano, Tomoaki Miyagawa, Kousuke Ueda, Haruhito Azuma, Masahiro Nozawa, Nobuyuki Hinata, Junichi Hori, Taiyo Otoshi, Nobuaki Shimizu, Mana Aizawa, Shingo Osada, Akiko Matsui, Mototsugu Oya, Masatoshi Eto, Yoshihiko Tomita, Nobuo Shinohara, Hirotsugu Uemura
Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART). International journal of urology : official journal of the Japanese Urological Association 31 (3) (2023)
Taigo Kato, Yuzo Nakano, Fumiya Hongo, Hidenori Katano, Tomoaki Miyagawa, Kousuke Ueda, Haruhito Azuma, Masahiro Nozawa, Nobuyuki Hinata, Junichi Hori, Taiyo Otoshi, Nobuaki Shimizu, Mana Aizawa, Shingo Osada, Akiko Matsui, Mototsugu Oya, Masatoshi Eto, Yoshihiko Tomita, Nobuo Shinohara, Hirotsugu Uemura
Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART). International journal of urology : official journal of the Japanese Urological Association (2023)
Leandro Blas, Masaki Shiota, Hideaki Miyake, Masayuki Takahashi, Mototsugu Oya, Norihiko Tsuchiya, Naoya Masumori, Hideyasu Matsuyama, Wataru Obara, Nobuo Shinohara, Kiyohide Fujimoto, Masahiro Nozawa, Kojiro Ohba, Chikara Ohyama, Katsuyoshi Hashine, Shusuke Akamatsu, Tomomi Kamba, Koji Mita, Momokazu Gotoh, Shuichi Tatarano, Masato Fujisawa, Yoshihiko Tomita, Shoichiro Mukai, Keiichi Ito, Tokiyoshi Tanegashima, Shoji Tokunaga, Masatoshi Eto, null null
Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study. International journal of urology : official journal of the Japanese Urological Association (2023)
Takahiro Osawa, Mototsugu Oya, Tohru Okanishi, Ryohei Kuwatsuru, Haruna Kawano, Yoshihiko Tomita, Yo Niida, Norio Nonomura, Takashi Hatano, Yasuhisa Fujii, Masashi Mizuguchi, Nobuo Shinohara
Clinical Practice Guidelines for tuberous sclerosis complex-associated renal angiomyolipoma by the Japanese Urological Association: Summary of the update. International journal of urology : official journal of the Japanese Urological Association (2023)
Masaki Murata, Masayuki Tasaki, Kazuhide Saito, Yuki Nakagawa, Masahiro Ikeda, Masato Akiyama, Naofumi Imai, Ichiei Narita, Kota Takahashi, Yoshihiko Tomita
Arteriolar hyalinization at 0-hour biopsy predicts long-term graft function in deceased kidney transplantation. International journal of urology : official journal of the Japanese Urological Association (2023)
Taigo Kato, Yuzo Nakano, Fumiya Hongo, Hidenori Katano, Tomoaki Miyagawa, Kousuke Ueda, Haruhito Azuma, Masahiro Nozawa, Nobuyuki Hinata, Junichi Hori, Taiyo Otoshi, Nobuaki Shimizu, Mana Aizawa, Shingo Osada, Akiko Matsui, Mototsugu Oya, Masatoshi Eto, Yoshihiko Tomita, Nobuo Shinohara, Hirotsugu Uemura
Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART). International journal of urology : official journal of the Japanese Urological Association 31 (3) (2023)
Taigo Kato, Yuzo Nakano, Fumiya Hongo, Hidenori Katano, Tomoaki Miyagawa, Kousuke Ueda, Haruhito Azuma, Masahiro Nozawa, Nobuyuki Hinata, Junichi Hori, Taiyo Otoshi, Nobuaki Shimizu, Mana Aizawa, Shingo Osada, Akiko Matsui, Mototsugu Oya, Masatoshi Eto, Yoshihiko Tomita, Nobuo Shinohara, Hirotsugu Uemura
Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART). International journal of urology : official journal of the Japanese Urological Association 31 (3) (2023)
James M G Larkin, Mototsugu Oya, Marcella Martignoni, Fiona Thistlethwaite, Paul Nathan, Moshe C Ornstein, Thomas Powles, Kathryn E Beckermann, Arjun V Balar, David McDermott, Sumati Gupta, George K Philips, Michael S Gordon, Hirotsugu Uemura, Yoshihiko Tomita, Jing Wang, Elisabete Michelon, Alessandra di Pietro, Toni K Choueiri
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial. The oncologist (2022)
Yoshihiko Tomita, Ko Kobayashi, Go Kimura, Mototsugu Oya, Hirotsugu Uemura, Hiroyuki Nishiyama, Matthew D Galsky, Federico Nasroulah, Sandra Collette, Edward Broughton, Keziban Ünsal-Kaçmaz, Yukinori Kamisuki, Dean F Bajorin
Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial. Japanese journal of clinical oncology (2022)
Yoshihiko Tomita, Go Kimura, Satoshi Fukasawa, Kazuyuki Numakura, Yutaka Sugiyama, Kazutoshi Yamana, Sei Naito, Koki Kabu, Mototsugu Oya, Mototsugu Oya
Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study). Japanese journal of clinical oncology 51 (6) (2021)
Meredith M Regan, Opeyemi A Jagede, Charlene M Mantia, Thomas Powles, Lillian Werner, Robert J Motzer, Nizar M Tannir, Chung-Han Lee, Yoshihiko Tomita, Martin H Voss, Elizabeth R Plimack, Toni K Choueiri, Brian I Rini, Hans J Hammers, Bernard Escudier, Laurence Albiges, Stephen Huo, Viviana Del Tejo, Brian Stwalley, Michael B Atkins, David F McDermott
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2021)